`ASSOCIATE
`
`(202) 772-8787
`MBODENSTEIN@SKGF.COM
`
`April 16, 2015
`
`Commissioner for Patents
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`
`
`
`
`<.flit/[III];V,.1
`
`Confirmation No. I 091
`Art Unit 1628
`
`Re:
`
`US. Track 1 Patent Application
`Appl. No. 14/500,409; Filed: September 29, 2014
`For:
`Buprenorphine-Wafer for Drug Substitution Therapy
`Inventors: OKSCHE et al.
`Our Ref: 1861.2700001/JMC/MSB
`
`Commissioner:
`
`Transmitted herewith for appropriate action are the following documents:
`
`1. Application Data Sheet; and
`
`2. Power of Attorney to Prosecute Applications Before the USPTO.
`
`The above-listed documents are filed electronically through EFS- Web.
`
`In the event that extensions of time are necessary to prevent abandonment of this patent
`application, then such extensions of time are hereby petitioned.
`
`The US. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
`or credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`
`Attorney for Applicants
`Registration No. 58,885
`
`MSB/lds
`
`Enclosures
`
`198923571.DOCX
`
`
`
`